Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.58 USD | -20.62% | -23.89% | -62.47% |
Jun. 07 | Brookline Capital Initiates SAB Biotherapeutics With Buy Rating, $8 Price Target | MT |
May. 30 | SAB Biotherapeutics, Inc. Announces Change of Chief Financial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.47% | 30M | |
+14.84% | 122B | |
+18.31% | 113B | |
+3.61% | 22.66B | |
-18.26% | 21.34B | |
-41.55% | 16.92B | |
-14.23% | 16.68B | |
-16.03% | 16.61B | |
-0.68% | 13.62B | |
+21.87% | 11.04B |
- Stock Market
- Equities
- SABS Stock
- News SAB Biotherapeutics, Inc.
- Chardan Research Adjusts SAB Biotherapeutics' Price Target to $3 From $7, Maintains Buy Rating